AvantGen Inc

AvantGen is a biotechnology company that specializes in antibody discovery and engineering. The company uses a proprietary yeast display technology to discover and optimize antibodies for therapeutic, diagnostic, and research applications. AvantGen's platforms include a robust yeast display system, large natural human antibody database, and fully human antibody libraries comprising over 100 billion antibody clones. The company also offers services such as affinity maturation, humanization, and rabbit monoclonal antibody generation. AvantGen partners with pharmaceutical, biotech, diagnostic, and government entities to discover and develop novel antibodies, and has established collaborations with companies such as Adcentrx Therapeutics to develop antibody-drug conjugates. Overall, AvantGen's core business is focused on enabling the discovery and development of novel antibody-based therapies through its innovative technology platforms and collaborative partnerships.

AvantGen is a privately-held biotechnology company developing next-generation therapeutic antibodies.

As a leader in yeast-based novel human antibody discovery, antibody humanization, antibody affinity maturation and optimization, AvantGen has developed a proprietary yeast display system, a proprietary fully human antibody (Germliner™) library and screening technologies.

Using this unique technology platform, AvantGen is rapidly expanding its pipeline in the areas of inflammation, cardiovascular disease, and oncology.

AvantGen collaborates with pharmaceutical and biotechnology companies to facilitate and speed their path to antibody-based therapeutic development through partnerships and licensing.

AvantGen also collaborates with the National Institutes of Health (NIH) to develop novel and renewable affinity captures for proteomic studies.

Technologies

Germliner™ Platform

Fully Human Antibody Discovery

Epitope-Guided Antibody Humanization

Antibody Optimization